EP 3920909 A4 20221130 - PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
Title (en)
PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT MELOXICAM
Title (fr)
COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU MÉLOXICAM
Publication
Application
Priority
- US 201962802198 P 20190206
- US 201962803756 P 20190211
- US 201962835613 P 20190418
- US 201962846311 P 20190510
- US 201962860705 P 20190612
- US 201962895933 P 20190904
- US 201962895956 P 20190904
- US 201962955905 P 20191231
- US 2020017046 W 20200206
Abstract (en)
[origin: WO2020163620A1] Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
IPC 8 full level
A61K 31/5415 (2006.01); A61K 9/20 (2006.01); A61K 9/24 (2006.01); A61K 31/4196 (2006.01); A61K 47/69 (2017.01); A61P 25/06 (2006.01)
CPC (source: EP IL KR)
A61K 9/0053 (2013.01 - KR); A61K 9/2009 (2013.01 - EP); A61K 9/209 (2013.01 - EP); A61K 31/4196 (2013.01 - EP IL KR); A61K 31/5415 (2013.01 - EP IL KR); A61K 47/02 (2013.01 - IL KR); A61K 47/40 (2013.01 - IL); A61K 47/6951 (2017.08 - EP KR); A61P 25/06 (2018.01 - EP IL KR); A61K 2300/00 (2013.01 - KR)
C-Set (source: EP)
Citation (search report)
- [Y] US 9821075 B2 20171121 - TABUTEAU HERRIOT [US]
- [Y] US 2009068262 A1 20090312 - ZALIT ILAN [IL], et al
- [XY] US 2004214861 A1 20041028 - SEIBERT KAREN [US]
- [XY] US 2018280306 A1 20181004 - TABUTEAU HERRIOT [US]
- [XY] ANONYMOUS: "Axosome Therapeutics announces AXS-07 for the treatment of migraine", PIPELINEREVIEW.COM, 28 November 2017 (2017-11-28), pages 1 - 2, XP055890967, Retrieved from the Internet <URL:https://pipelinereview.com/index.php/2017112866624/Small-Molecules/Axsome-Therapeutics-Announces-AXS-07-for-the-Treatment-of-Migraine.html> [retrieved on 20220214]
- See also references of WO 2020163620A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
Designated validation state (EPC)
KH MA MD TN
DOCDB simple family (publication)
WO 2020163620 A1 20200813; AU 2020218253 A1 20210812; AU 2020218253 B2 20230223; AU 2023202545 A1 20230518; BR 112021015467 A2 20211005; CA 3128940 A1 20200813; CA 3128940 C 20231107; CA 3213549 A1 20200813; CL 2021002070 A1 20220401; CN 113423397 A 20210921; CO 2021010380 A2 20210930; CR 20210420 A 20211222; EC SP21060962 A 20211130; EP 3920909 A1 20211215; EP 3920909 A4 20221130; IL 285389 A 20210930; JP 2022519670 A 20220324; JP 2023062144 A 20230502; JP 2024026732 A 20240228; JP 7237386 B2 20230313; JP 7420990 B2 20240123; KR 20210118880 A 20211001; MA 54904 A 20211215; MX 2021009435 A 20210910; PE 20212157 A1 20211109; SG 11202107926X A 20210830
DOCDB simple family (application)
US 2020017046 W 20200206; AU 2020218253 A 20200206; AU 2023202545 A 20230427; BR 112021015467 A 20200206; CA 3128940 A 20200206; CA 3213549 A 20200206; CL 2021002070 A 20210805; CN 202080012487 A 20200206; CO 2021010380 A 20210806; CR 20210420 A 20200206; EC DI202160962 A 20210817; EP 20752178 A 20200206; IL 28538921 A 20210804; JP 2021545919 A 20200206; JP 2023025218 A 20230221; JP 2024002855 A 20240111; KR 20217026519 A 20200206; MA 54904 A 20200206; MX 2021009435 A 20200206; PE 2021001288 A 20200206; SG 11202107926X A 20200206